Please login to the form below

Not currently logged in
Email:
Password:

S-A appoints president, global R&D

Sanofi-aventis has announced the appointment of former director of the US NIH Dr Elisa Zerhouni as president, global R&D

Sanofi-aventis (S-A) has announced the appointment of Dr Elisa Zerhouni as president, global R&D, effective January 2011.

Covering medicines and vaccines, Dr Zerhouni will also join the executive committee and the management committee.

Having worked as scientific advisor to S-A CEO, Christopher Viehbacher, since February 2009, Dr Zerhouni has helped redesign the company's R&D model to focus on increased innovation to tackle currently unmet patient needs.

"Through his vast experience and visionary approach, he has provided excellent advice and insight and has been central in implementing what is now one of the most promising R&D models in healthcare," said Viehbacher.

"I am delighted that a world-renowned figure such as Elias is onboard to lead and drive our R&D organisation to ensure we make the maximum impact on health and deliver what patients need in the future."

Currently serving as professor of Radiology and Biomedical engineering and senior adviser for Johns Hopkins Medicine, Dr Zerhouni's previous roles include director of the US National Institutes of Health from 2002 to 2008.

A native of Algeria, he has also received the Legion of Honour from the French National Order and is Senior Fellow of the Bill and Melinda Gates Foundations.

S-A also announced Dr Marc Cluzel's resignation as executive vice president, though Cluzel will continue to assist Zerhouni in an advisory role.

Viehbacher said: "I would like to sincerely thank Marc for his long-term contribution. His passion for science and commitment thus far has ensured a readiness to lead the implementation of the transformation of R&D over the past few years."

14th December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics